Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer
2021 · Journal of Translational Medicine · 67 citations
https://doi.org/10.1186/s12967-021-02722-8
L
Lifei Shen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
34
Papers
301
Citations
8
h-index
8
i10-index
Lifei Shen is an academic researcher from Peking University. The author has contributed to research in topics: Endometrial and Cervical Cancer Treatments & Cancer Genomics and Diagnostics & Genetic factors in colorectal cancer. The author has an h-index of 8, co-authored 29 publications.
Papers by this author
worksNeoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
2023 · BMC Cancer · 28 citations
https://doi.org/10.1186/s12885-023-10517-x
Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial
2022 · Trials · 12 citations
https://doi.org/10.1186/s13063-021-05986-z
The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial)
2024 · Journal of Ovarian Research · 6 citations
https://doi.org/10.1186/s13048-024-01468-3
TRIM4 modulates the ubiquitin-mediated degradation of hnRNPDL and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer
2024 · Frontiers of Medicine · 2 citations
https://doi.org/10.1007/s11684-024-1103-5
Additional file 1 of Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.13710992
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat